Literature DB >> 32396533

Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis.

Andrea Fava1, Jill Buyon2, Chandra Mohan3, Ting Zhang3, H Michael Belmont2, Peter Izmirly2, Robert Clancy2, Jose Monroy Trujillo4, Derek Fine4, Yuji Zhang5,6, Laurence Magder5, Deepak A Rao7, Arnon Arazi8, Celine C Berthier9, Anne Davidson10, Betty Diamond10, Nir Hacohen8, David Wofsy11, William Apruzzese7, Soumya Raychaudhuri12,13,14,15,16, Michelle Petri1.   

Abstract

Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE), has a heterogeneous clinical and pathological presentation. For example, proliferative nephritis identifies a more aggressive disease class that requires immunosuppression. However, the current classification system relies on the static appearance of histopathological morphology, which does not capture differences in the inflammatory response. Therefore, a biomarker grounded in the disease biology is needed in order to understand the molecular heterogeneity of lupus nephritis and identify immunologic mechanism and pathways. Here, we analyzed the patterns of 1000 urine protein biomarkers in 30 patients with active lupus nephritis. We found that patients stratify over a chemokine gradient inducible by IFN-γ. Higher values identified patients with proliferative lupus nephritis. After integrating the urine proteomics with the single-cell transcriptomics of kidney biopsies, we observed that the urinary chemokines defining the gradient were predominantly produced by infiltrating CD8+ T cells, along with natural killer and myeloid cells. The urine chemokine gradient significantly correlated with the number of kidney-infiltrating CD8+ cells. These findings suggest that urine proteomics can capture the complex biology of the kidney in lupus nephritis. Patient-specific pathways could be noninvasively tracked in the urine in real time, enabling diagnosis and personalized treatment.

Entities:  

Keywords:  Autoimmunity; Lupus; Nephrology; Proteomics; Th1 response

Mesh:

Substances:

Year:  2020        PMID: 32396533      PMCID: PMC7406291          DOI: 10.1172/jci.insight.138345

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  48 in total

Review 1.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

2.  Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.

Authors:  Melissa E Munroe; Rufei Lu; Yan D Zhao; Dustin A Fife; Julie M Robertson; Joel M Guthridge; Timothy B Niewold; George C Tsokos; Michael P Keith; John B Harley; Judith A James
Journal:  Ann Rheum Dis       Date:  2016-01-25       Impact factor: 19.103

3.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

4.  Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4+ and CD8+ T cells and macrophages.

Authors:  Jan Klocke; Katharina Kopetschke; Anna-Sophie Grießbach; Valerie Langhans; Jens Y Humrich; Robert Biesen; Duska Dragun; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten; Philipp Enghard
Journal:  Eur J Immunol       Date:  2016-11-21       Impact factor: 5.532

Review 5.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

6.  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Daniel J Wallace; Richard A Furie; Yoshiya Tanaka; Kenneth C Kalunian; Marta Mosca; Michelle A Petri; Thomas Dörner; Mario H Cardiel; Ian N Bruce; Elisa Gomez; Tara Carmack; Amy M DeLozier; Jonathan M Janes; Matthew D Linnik; Stephanie de Bono; Maria E Silk; Robert W Hoffman
Journal:  Lancet       Date:  2018-07-21       Impact factor: 79.321

7.  A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.

Authors:  Marcelo De Rosa; Francisco Azzato; Jorge E Toblli; Graciela De Rosa; Federico Fuentes; Haikady N Nagaraja; Ryan Nash; Brad H Rovin
Journal:  Kidney Int       Date:  2018-07-23       Impact factor: 10.612

8.  Value of repeat biopsy in lupus nephritis flares.

Authors:  G Greloni; M Scolnik; J Marin; E Lancioni; C Quiroz; J Zacariaz; P De la Iglesia Niveyro; S Christiansen; M A Pierangelo; C F Varela; G J Rosa-Diez; L J Catoggio; E R Soriano
Journal:  Lupus Sci Med       Date:  2014-04-01

9.  Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.

Authors:  Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

10.  CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq.

Authors:  Tamar Hashimshony; Naftalie Senderovich; Gal Avital; Agnes Klochendler; Yaron de Leeuw; Leon Anavy; Dave Gennert; Shuqiang Li; Kenneth J Livak; Orit Rozenblatt-Rosen; Yuval Dor; Aviv Regev; Itai Yanai
Journal:  Genome Biol       Date:  2016-04-28       Impact factor: 13.583

View more
  20 in total

Review 1.  Cellular and molecular interrogation of kidney biopsy specimens.

Authors:  Michael T Eadon; Pierre C Dagher; Tarek M El-Achkar
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-01       Impact factor: 2.894

2.  Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.

Authors:  Andrea Fava; Deepak A Rao; Chandra Mohan; Ting Zhang; Avi Rosenberg; Paride Fenaroli; H Michael Belmont; Peter Izmirly; Robert Clancy; Jose Monroy Trujillo; Derek Fine; Arnon Arazi; Celine C Berthier; Anne Davidson; Judith A James; Betty Diamond; Nir Hacohen; David Wofsy; Soumya Raychaudhuri; William Apruzzese; Jill Buyon; Michelle Petri
Journal:  Arthritis Rheumatol       Date:  2022-04-16       Impact factor: 15.483

3.  History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis.

Authors:  Andrea Fava; Paride Fenaroli; Avi Rosenberg; Serena Bagnasco; Jessica Li; Jose Monroy-Trujillo; Derek Fine; Mohamed G Atta; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

Review 4.  Cutaneous and systemic connections in lupus.

Authors:  Mitra P Maz; J Michelle Kahlenberg
Journal:  Curr Opin Rheumatol       Date:  2020-11       Impact factor: 4.941

Review 5.  Transcriptomic studies of systemic lupus erythematosus.

Authors:  Masahiro Nakano; Yukiko Iwasaki; Keishi Fujio
Journal:  Inflamm Regen       Date:  2021-04-09

Review 6.  Insights Gained and Future Outlook From scRNAseq Studies in Autoimmune Rheumatic Diseases.

Authors:  Zihan Zheng; Ling Chang; Jingyi Li; Yuzhang Wu; Guangxing Chen; Liyun Zou
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

7.  Glycosphingolipid Levels in Urine Extracellular Vesicles Enhance Prediction of Therapeutic Response in Lupus Nephritis.

Authors:  Brian Troyer; Jessalyn Rodgers; Bethany J Wolf; James C Oates; Richard R Drake; Tamara K Nowling
Journal:  Metabolites       Date:  2022-02-01

Review 8.  Interferons in Systemic Lupus Erythematosus.

Authors:  Sirisha Sirobhushanam; Stephanie Lazar; J Michelle Kahlenberg
Journal:  Rheum Dis Clin North Am       Date:  2021-06-10       Impact factor: 2.032

9.  New biomarkers in SLE: from bench to bedside.

Authors:  Riccardo Capecchi; Ilaria Puxeddu; Federico Pratesi; Paola Migliorini
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

10.  A Variant of sNASP Exacerbates Lymphocyte Subset Disorder and Nephritis in a Spontaneous Lupus Model Sle1.Yaa Mouse.

Authors:  Jianye Zhang; Xiaoping Du; Hui Wang; Yatao Bao; Meng Lian; Zhiwei Xu; Jiyu Ju
Journal:  Mediators Inflamm       Date:  2021-10-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.